BD will pay a $175 million civil penalty to settle charges from the Securities and Exchange Commission that the company misled investors about problems with its Alaris infusion pumps. The SEC ...

According to the SEC’s order, BD determined in 2016 that software changes made to the Alaris pump required regulatory clearance from the Food and Drug Administration (FDA). However, BD did not ...

BD decided to continue to selling the Alaris pumps with the improvement without the clearance for it. The SEC said that by January 2019, the company found more than 25 flaws with the software that ...

relate to matters concerning BD Alaris that occurred more than four years ago. As part of the settlement, BD has agreed to pay $175 million to the SEC, an amount that was reserved and disclosed in ...

Becton, Dickinson and Co. reached an agreement with the U.S. Securities and Exchange Commission (SEC) to resolve an investigation related to allegations that the company misled investors regarding the ...

BD had a run-in with the SEC involving its BD Alaris Infusion System line and how it was presented to investors through its filings from 2020. Without admitting or denying fault, the company has ...